26
Participants
Start Date
July 31, 2016
Primary Completion Date
December 31, 2019
Study Completion Date
December 31, 2019
Fostamatinib 150 mg bid
Fostamatinib 150 mg bid. The dose of Fostamatinib may be reduced at any time to as low as 100 mg PO once daily (qd) if dose limiting adverse events are observed.
Montefiore Medical Center, The Bronx
Roswell Park Cancer Institute, Buffalo
MedStar Georgetown University Hospital, Washington D.C.
Rcca Md Llc, Bethesda
Johns Hopkins University School Of Medicine, Baltimore
West Virginia University, Morgantown
Brody School of Medicine at East Carolina University, Greenville
"W.G. Bill Hefner VA Medical Center", Salisbury
M. Francisco Gonzalez, M.D., P.A., Sumter
Mid-Florida Hematology & Oncology Centers, P.A., Orange City
Montgomery Cancer Center, Mount Sterling
The Ohio State University Wexner Medical Center, Columbus
Promedica Flower Hospital, Sylvania
Cleveland Clinic Foundation, Cleveland
MidMichigan Health Cancer Center, Midland
Froedtert Hospital, Milwaukee
University of Minnesota, Minneapolis
Clear Lake Specialties, Webster
Texas Oncology San Antonio Medical Center, San Antonio
Huntsman Cancer Institute, Salt Lake City
University of Utah, Salt Lake City
Banner MD Anderson Cancer Center, Gilbert
Arizona Oncology Associates, PC, Tucson
LAC/USC Health Center, Los Angeles
The Oncology Institute of Hope and Innovation, Whittier
UC San Diego Moores Cancer Center, La Jolla
Loma Linda University Cancer Center, Loma Linda
University of California at San Francisco, San Francisco
University of Washington, Seattle
Massachusetts General Hospital, Boston
Robert Wood Johnson University Hospital, New Brunswick
University of Alberta Hospital, Edmonton
Hamilton Health Sciences- McMaster University Medical Centre, Hamilton
Victoria Hospital, London
St. Michael's Hospital, Toronto
Jewish General Hospital, Montreal
Lead Sponsor
Rigel Pharmaceuticals
INDUSTRY